Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Liminatus Pharma Inc. (LIMN) had Income from Continuous Operations of $-8.50M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-8.50M |
|
-- |
|
-- |
|
$1.15M |
|
$-1.15M |
|
$-7.35M |
|
$-8.50M |
|
$-8.50M |
|
$-8.50M |
|
|
Income from Continuous Operations |
$-8.50M |
$-8.50M |
|
$-8.50M |
|
$-1.15M |
|
$-1.15M |
|
23.75M |
|
23.75M |
|
$2.19 |
|
$2.19 |
|
| Balance Sheet Financials | |
$0.50M |
|
$0.01M |
|
$0.01M |
|
$0.51M |
|
$10.30M |
|
-- |
|
$0.03M |
|
$10.33M |
|
$-9.81M |
|
$-9.81M |
|
$-9.81M |
|
27.07M |
|
| Cash Flow Statement Financials | |
$-9.96M |
|
$-0.79M |
|
$11.03M |
|
$0.06M |
|
$0.34M |
|
$0.28M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.05 |
|
-- |
|
-- |
|
-- |
|
-0.15 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-9.98M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
86.57% |
|
86.57% |
|
-1656.94% |
|
86.57% |
|
$-0.36 |
|
$-0.42 |
|
$-0.42 |
|